![rocheshanghai](https://pharmafile.com/wp-content/uploads/2016/05/rocheshanghai-798x1024.jpg)
FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq
pharmafile | May 19, 2016 | News story | Research and Development, Sales and Marketing | FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq
Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) for the treatment of patients with a specific type of bladder cancer.
The drug is indicated for patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during of following platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before surgery or after surgery. Urothelial carcinoma accounts for 90% of all bladder cancers.
Under an accelerated approval, the FDA allows conditional approval of a medicine that fills an unmet medical need for a serious condition based on early clinical signs showing safety and efficacy. This approval is based on the Phase II IMvigor study, which achieved objective response rates of 14.8% across all patients. Roche is set to evaluate the drug in a Phase III study.
Sandra Horning, chief medical officer at Roche, says: “Tecentriq is a new medicine that can work with the immune system to treat people with a type of bladder cancer that progressed after platinum-based chemotherapy.”
Sean Murray
Related Content
![](https://pharmafile.com/wp-content/uploads/2024/01/shutterstock_2154643979-300x200.jpg)
IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer
Precision medicine oncology company IDEAYA Biosciences has announced that the first patient in the IDEAYA-sponsored …
![](https://pharmafile.com/wp-content/uploads/2023/05/shutterstock_418295602-300x169.jpg)
FDA approves AbbVie’s Skyrizi for UC treatment
AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) …
![](https://pharmafile.com/wp-content/uploads/2023/08/nappy-5RDjrd5GXuM-unsplash-300x200.jpg)
FDA approves Merck’s Capvaxive for prevention of pneumococcal disease
Merck, known as MSD outside of the US and Canada, has announced that the US …